- Research works
- 7 fractional, all time
- Citations
- 43 6.2 per fractional work
- Top-10% rate
- 12.0% record average 16.5%
- Open access
- 68% world 28%
Not ranked overall: Cullinan Oncology (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Cullinan Oncology (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immunotherapy and Immune Responses and Immune Cell Function and Interaction.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 2 CAR-T cell therapy research Oncology 1 works
- 3 Immunotherapy and Immune Responses Immunology 0 works
- 4 Immune Cell Function and Interaction Immunology 0 works
- 5 Cancer Research and Treatments Biotechnology 0 works
- 6 Biosimilars and Bioanalytical Methods Immunology 0 works
- 7 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
- 9 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
- 10 Virus-based gene therapy research Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
Other research institutions in Cambridge
- Foundation Medicine (United States)
- GE Vernova (United States)
- Communicating Diet and Activity Research
- Thoth Open Metadata
- Immuneering (United States)
- Cancer Imaging Centre
- Stanley Center for Psychiatric Research
- eLife Sciences Publications
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.